ClinicalTrials.gg
RecruitingNCT02844751Updated Oct 14, 2025

Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee

A Phase 2 interventional study of [StroMed + platelet rich plasma (PRP)] and [PRP] platelet rich plasma in Osteoarthritis, sponsored by VivaTech International, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by VivaTech International, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Jul 2015, registered Jul 2016).
  • Started Jul 2015; still recruiting 11 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4,000
Allocation
Non-randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies testing platelet rich plasma in Osteoarthritis — 6 open to participants now, 6 under way, 1 of them phase 3. platelet rich plasma · Osteoarthritis.

Planned enrollment
2nd of 28
4,000 · median 70
Started
2015
with 1 other
Phase 2
2 of 28
2 open now
Registered
12th of 28
by date

Among the 28 studies testing platelet rich plasma in Osteoarthritis, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2015, is one of 2 in phase 2, and was the 12th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

6 of the 28 studies testing platelet rich plasma in Osteoarthritis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About platelet rich plasma

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing platelet rich plasma in Osteoarthritis, or all of them as a file.
02

Study summary

This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the knee. Follow-up will consist of a larger sample including 4,000 patients.

Read the detailed description

This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the knee. Follow-up will consist of a larger sample including 4,000 patients.

Patients will be treated for Osteoarthritis (OA) of the knee due to degeneration or chronic injury. They will be treated with autologous Stromed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU) and Platelet Rich Plasma (PRP) processed by RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints.

Cohort 1 will include PRP treatments at time of initial StroMed treatment plus at 1 week, 2 weeks and 1 month.

Cohort 2 will include PRP treatments at time of initial StroMed treatment plus at 1 month and 2 months.

Patient outcomes will be tracked with a follow up MRI at various endpoints to 6 months, laboratory tests for inflammation markers, and knee injury and osteoarthritis outcome score (KOOS) questionnaires. SF-36 forms (a quality of life measure) and numerical rating scales (NRS) will also be used to assess safety and efficacy of treatment, as well as any reduction in patient medication and/or delay in pending knee replacement therapy.

03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with indication of Osteoarthritis, grade 2 or more. Can be from degeneration or chronic injury.
  2. Patients range from 18-90 years of age.
  3. Patients must be able to comply with treatment plan, laboratory tests and periodic interviews.
  4. Patients with adequate renal function, Creatinine ≤ 1.5 mg/dl.
  5. Patients with adequate cardiac and respiratory function.
  6. Patients with adequate blood coagulation activity, PT() \< 1.5, APTT
  7. Patients must have adequate immune system function, with no known immunodeficiency disease.
  8. Greater than 6 months knee pain on the index side (left or right knee).

Exclusion criteria

Exclusion Criteria:

  1. Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision
  2. Presence of acute or unstable cardiovascular and cerebrovascular (stroke).
  3. Diagnosis of a in the 6 months prior to screening.
  4. Patients infected with , C or .
  5. Patients with (BMI) > 40kg/m2
  6. Presence of active infection.
  7. Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study.
  8. Conditions/therapies/factors which could confound or interfere with the evaluation of pain/mobility including, but not limited to:

    1. Knee instability.
    2. A varus/valgus deformity of more than 10o, a deformity requiring osteotomy or complex surgery.
    3. Gout or pseudo gout
    4. Treatments with strong opioid drugs in the previous 4 weeks for other pain rather than knee osteoarthritis
    5. injection at treatment site within 1 month
    6. Consistent use of NSAIDs within 48 hours of procedure.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4,000 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Interventions assigned by Principal Investigator

    Biological: [StroMed + platelet rich plasma (PRP)] · Biological: [PRP] platelet rich plasma

  • Experimental
    Cohort 2

    Interventions assigned by Principal Investigator

    Biological: [StroMed + platelet rich plasma (PRP)] · Biological: [PRP] platelet rich plasma

Interventions

  • Biological[StroMed + platelet rich plasma (PRP)]

    \[Day 0\] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.

  • BiologicalPlatelet rich plasmaStudies of Platelet rich plasmaPlatelet rich plasma pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 7,14 and 30

  • BiologicalPlatelet rich plasmaStudies of Platelet rich plasmaPlatelet rich plasma pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 30 and 60

06

What researchers measure

Primary outcomes

  1. Change is being assessed for the KOOS survey (Knee Osteoarthritis Outcome Score)

    Knee osteoarthritis outcome score

    Time frame: 0, 2, 6 months

Secondary outcomes

  1. Change is being assessed by MRI of afflicted joint

    Looking for cartilage regrowth via MRI

    Time frame: 0 and (6 - 12 months optional)

  2. Change is being assessed for the SF36 survey (Short Form Health Survey)

    Short Form health Survey

    Time frame: 0,2,6 months

  3. Change is being assessed for the NRS survey (Numerical Rating Scale for Pain)

    Numerical Rating Scale for pain

    Time frame: 0,2,6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — VivaTech will monitor data and decide if/when data can be shared

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2015 (actual). Primary completion is estimated for Aug 2026, 133 months after the start.

Of 54 industry-sponsored phase 2 interventional studies under Osteoarthritis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's planned 133 months is above that.

Counting every sponsor, half of 82 studies reached it within 19 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2016
First posted
Jul 26, 2016
StartActual
Jul 2015
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02844751
Lead sponsor
VivaTech International, Inc.
Responsible party
Sponsor
First posted
Jul 26, 2016
Start date
Jul 2015
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Oct 14, 2025

Study contacts

Scott M Herkes, MBA
Contact
scott.herkes@gmail.com
855-984-8287
Michael P Hutchinson, DVM
Contact
drmike@vivatechusa.com
412-503-3788
Mark LoDico, MD
principal investigator · Advanced Regenerative Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Platelet rich plasma

Start the discussion